Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05358847 · ClinicalTrials.gov registry record · NA
Treatment for Cellulite Appearance
A NA study, sponsored by Sofwave Medical.
- Completed
- Registry status
- NA
- Development phase
- 69
- Enrollment target
NCT05358847: Completed NA study, sponsored by Sofwave Medical.
NCT05358847 is a NA study that has completed, run by Sofwave Medical. The registered enrollment target is 69 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05358847, a NA study, has completed, sponsored by Sofwave Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 69 participants
- Enrollment target
Study Summary
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
Primary Outcome
following Sofwave treatments based on 6 points simplified Cellulite Severity Scale (CSS), as evaluated by independent masked reviewers.
Interventions
- DEVICE Sofwave
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2021-11-21 |
| Est. Completion | 2023-03-01 |
| Phase | NA |
What the finished NCT05358847 record still lists
NCT05358847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Sofwave is the first listed.
NCT05358847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05358847 about?
NCT05358847 is a clinical study titled "Treatment for Cellulite Appearance". Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
What is the current status of trial NCT05358847?
This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2021-11-21. Estimated completion is 2023-03-01.
What interventions are being tested in trial NCT05358847?
The interventions under investigation include: Sofwave (DEVICE).
Who is sponsoring clinical trial NCT05358847?
This trial is sponsored by Sofwave Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05358847's enrollment target sits among peer trials
69 1133rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI